一图读懂药物临床试验登记与信息公示

2019-10-30 陈晓艺 王海学 裴小静 姚 临床试验管理处 珠星

文字:临床试验管理处 王海学 裴小静 姚珠星 绘图:陈晓艺 审核:周刚 曹永芳 陈方











文字:临床试验管理处 王海学 裴小静 姚珠星
绘图:陈晓艺
审核:周刚 曹永芳 陈方

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=901093, encodeId=3eea90109389, content=真皮, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=gqylhd, createdTime=Sun Nov 22 07:16:45 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884950, encodeId=0913884950b4, content=好得很, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Sun Sep 13 14:22:24 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811447, encodeId=3b8381144e96, content=除了五条杠之外,咋啥都没有呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5bf5386939, createdName=ms1000001689299389, createdTime=Thu Aug 20 16:49:56 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480928, encodeId=d36f148092828, content=<a href='/topic/show?id=96a08e64833' target=_blank style='color:#2F92EE;'>#药物临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87648, encryptionId=96a08e64833, topicName=药物临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65ed7724096, createdName=1508842480_96220439, createdTime=Fri Nov 01 00:21:00 CST 2019, time=2019-11-01, status=1, ipAttribution=)]
    2020-11-22 gqylhd

    真皮

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=901093, encodeId=3eea90109389, content=真皮, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=gqylhd, createdTime=Sun Nov 22 07:16:45 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884950, encodeId=0913884950b4, content=好得很, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Sun Sep 13 14:22:24 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811447, encodeId=3b8381144e96, content=除了五条杠之外,咋啥都没有呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5bf5386939, createdName=ms1000001689299389, createdTime=Thu Aug 20 16:49:56 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480928, encodeId=d36f148092828, content=<a href='/topic/show?id=96a08e64833' target=_blank style='color:#2F92EE;'>#药物临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87648, encryptionId=96a08e64833, topicName=药物临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65ed7724096, createdName=1508842480_96220439, createdTime=Fri Nov 01 00:21:00 CST 2019, time=2019-11-01, status=1, ipAttribution=)]
    2020-09-13 ms1000000302953060

    好得很

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=901093, encodeId=3eea90109389, content=真皮, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=gqylhd, createdTime=Sun Nov 22 07:16:45 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884950, encodeId=0913884950b4, content=好得很, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Sun Sep 13 14:22:24 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811447, encodeId=3b8381144e96, content=除了五条杠之外,咋啥都没有呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5bf5386939, createdName=ms1000001689299389, createdTime=Thu Aug 20 16:49:56 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480928, encodeId=d36f148092828, content=<a href='/topic/show?id=96a08e64833' target=_blank style='color:#2F92EE;'>#药物临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87648, encryptionId=96a08e64833, topicName=药物临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65ed7724096, createdName=1508842480_96220439, createdTime=Fri Nov 01 00:21:00 CST 2019, time=2019-11-01, status=1, ipAttribution=)]
    2020-08-20 ms1000001689299389

    除了五条杠之外,咋啥都没有呀

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=901093, encodeId=3eea90109389, content=真皮, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c31528806, createdName=gqylhd, createdTime=Sun Nov 22 07:16:45 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884950, encodeId=0913884950b4, content=好得很, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Sun Sep 13 14:22:24 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811447, encodeId=3b8381144e96, content=除了五条杠之外,咋啥都没有呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5bf5386939, createdName=ms1000001689299389, createdTime=Thu Aug 20 16:49:56 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480928, encodeId=d36f148092828, content=<a href='/topic/show?id=96a08e64833' target=_blank style='color:#2F92EE;'>#药物临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87648, encryptionId=96a08e64833, topicName=药物临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=65ed7724096, createdName=1508842480_96220439, createdTime=Fri Nov 01 00:21:00 CST 2019, time=2019-11-01, status=1, ipAttribution=)]

相关资讯

国内外临床试验保险行业发展现状比较

国内新药临床申请、临床试验呈现逐年攀升的趋势,这将导致临床不良风险事件(SAE)发生的可能性增加,在这种情况下,无论申办方还是受试者,都需要通过有效的第三方保险来降低自身风险。我国药物临床试验保险发展才起步,存在政策不完善、行业非标化、保险公司不专业以及申办方或受试者投保意识低等问题。探索临床试验保险的改进方向,为临床试验参与双方保驾护航是我国目前临床试验保险行业需要努力的方向。一、药物临床试

Plos Med:一个神奇的临床试验:不是免疫治疗,不是靶向治疗,却极受病人欢迎

丹麦科学家最近发表了一项研究结果,是一项在前列腺癌患者中进行的随机对照临床试验。

礼来的聚乙二醇白细胞介素-10(pegilodecakin)在胰腺癌临床试验中失败

在SEQUOIA试验中,将礼来的聚乙二醇化的白细胞介素10(pegilodecakin)与标准化疗FOLFOX方案(亚叶酸、5-氟尿嘧啶和奥沙利铂)联合用于转移性胰腺癌患者的二线治疗,这些患者在基于一线吉西他滨治疗后疾病再次进展。

又一批药物将接受临床试验数据核查

昨日(10月15日),国家药品监督管理局官网发布公告称,决定对新收到的7个已完成临床试验申报生产的药品注册申请进行临床试验数据核查。

爱丁堡大学的临床试验验证了其新型细胞疗法在肝硬化患者中的安全性

爱丁堡大学MRC再生医学中心的研究人员将一种新的细胞疗法在肝硬化患者中进行了测试,未发现明显的不良反应。

通用流感疫苗人体试验结果来了!有望更全面更长期预防

季节性流感病毒在全球范围内,每年可导致多达65万例死亡和300-500万例严重感染。世界卫生组织建议将每年接种流感疫苗作为预防流感的最有效方法。